Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization
Journal of Medicinal Chemistry · 12.10.2023 · 66 (19) · 13400-13415
DOI: 10.1021/acs.jmedchem.3c00554 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 22.09.2023. Verfasst von Magnus Nilsson und 19 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Chemistry, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden. Hauptthemen laut MEDLINE: Janus Kinase 1, Protein Kinase Inhibitors. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 78 Literaturangaben.
Abstract (Originalsprache)
JAK-STAT cytokines are critical in regulating immunity. Persistent activation of JAK-STAT signaling pathways by cytokines drives chronic inflammatory diseases such as asthma. Herein, we report on the discovery of a highly JAK1-selective, ATP-competitive series of inhibitors having a 1000-fold selectivity over other JAK family members and the approach used to identify compounds suitable for inhaled administration. Ultimately, compound 16 was selected as the clinical candidate, and upon dry powder inhalation, we could demonstrate a high local concentration in the lung as well as low plasma concentrations, suggesting no systemic JAK1 target engagement. Compound 16 has progressed into clinical trials. Using 16, we found JAK1 inhibition to be more efficacious than JAK3 inhibition in IL-4-driven Th2 asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medicinal Chemistry, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden.
- Bioscience, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden.
- Structure and Biophysics, Research and Early Development, Discovery Science, BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden.
- Early Product Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden.
- Oncology R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States.
- DMPK, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden.
ORCID-Profile: Magnus Nilsson, Mia Collins, Neil P Grimster, Johan R Johansson, Jason G Kettle
Zitieren
APA
Nilsson, M., Berggren, K., Berglund, S., Cerboni, S., Collins, M., Dahl, G., Elmqvist, D., Grimster, N. P., Hendrickx, R., Johansson, J. R., Kettle, J. G., Lepistö, M., Rhedin, M., Smailagic, A., Su, Q., Wennberg, T., Wu, A., Österlund, T., Naessens, T., & Mitra, S. (2023). Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization. Journal of Medicinal Chemistry, 66(19), 13400-13415. https://doi.org/10.1021/acs.jmedchem.3c00554
Vancouver
Nilsson M, Berggren K, Berglund S, Cerboni S, Collins M, Dahl G, et al. Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization. Journal of Medicinal Chemistry. 2023;66(19):13400-13415. doi:10.1021/acs.jmedchem.3c00554
BibTeX
@article{Nilsson2023,
author = {Nilsson, Magnus and Berggren, Kristina and Berglund, Susanne and Cerboni, Silvia and Collins, Mia and Dahl, Göran and Elmqvist, David and Grimster, Neil P and Hendrickx, Ramon and Johansson, Johan R and Kettle, Jason G and Lepistö, Matti and Rhedin, Magdalena and Smailagic, Amir and Su, Qibin and Wennberg, Tiiu and Wu, Allan and Österlund, Torben and Naessens, Thomas and Mitra, Suman},
title = {Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {19},
pages = {13400--13415},
doi = {10.1021/acs.jmedchem.3c00554}
}
EUVIMED